The Gut - PRO Study

NCT ID
NCT07413744
Registry status
Recruiting
Study type
Interventional
Phase
Phase 1
Sponsor
University of Wisconsin, Madison
Conditions
Alzheimer Disease

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: Probiotic Supplementation Safety and Feasibility Study in Preclinical Alzheimer's Disease

Enrollment: 40 participants (Estimated).

What is being studied

  • Intervention: Diet, Food, and Nutrition
  • Intervention: Dietary Supplements
  • Intervention: Food
  • Intervention: Food and Beverages
  • Intervention: Physiological Phenomena
  • Other: Placebo
  • Drug: Probiotic
  • Intervention: Probiotics

Who may be eligible

Ages
60 Years to no maximum
Sex
All
Healthy volunteers accepted
Yes

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * MCI/AD or cognitively unimpaired, referred from a Wisconsin clinic that is part of the Wisconsin Alzheimer's Institute's (WAI) network, or recruited from the community. May have participated in: * Alzheimer's Disease Research Center (ADRC) clinical core study (2011-0030) * ADCP (26695, MCW IRB) * Synapse study (2018-1283) * ADRC Recruitment Registry (2016-0735) * At least 60 years of age or older * Good general health (other than cognitive impairment/dementia) with no conditions/medications affecting the gut microbiome (see exclusion criteria below) * Willing and able to comply with all study procedures for the duration of the study * Able to provide signed and dated informed consent form * Participant is not pregnant, lactating or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile) * Able to take oral medications * An informant to answer questionnaires about the participant Additional inclusion criteria for unimpaired participants: * Has MOCA score that falls within the range defined for cognitively healthy individuals Additional inclusion criteria for participants with MCI/AD * Abnormal cognitive function documented by neuropsychological testing * ADRC (2015-0030) Consensus Diagnosis Conference indicates dementia or MCI due to AD (for ADRC, ADCP, and Synapse participants only) * Meets NIA-AA criteria for MCI or AD. Exclusion Criteria: * Active or previous (within 6 months) participation in an Alzheimer's clinical intervention/trial (can be included if previously enrolled in placebo or control group) * Standard clinical care for dementia and medications used to treat MCI and Alzheimer's disease are acceptable, including monoclonal antibody therapy * Significant neurologic disease: Any significant neurologic disease, such as Parkinson's disease, stroke, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, subdural hematoma, multiple sclerosis, seizure disorder, or other significant deficits other than Alzheimer's or Mild Cognitive Impairment * Alcohol/substance: history of alcohol/substance dependence in the past year. * Significant medical illness: any significant systemic illness or unstable medical condition occurring during ADRC participation that could affect cognition (other than MCI/AD). Examples include malignant cancer, chemotherapy, HIV, untreated thyroid disease, heart failure, or renal insufficiency * Current diagnosis with diabetes * Illiterate, blind, or non-English speaking * Known periodic antibiotic use (i.e., prior to dental appointments) * Oral PS-specific exclusion criteria: * Inability (e.g., dysphagia) or unwilling to swallow capsules * Active gastrointestinal infection at time of enrollment * Known or suspected toxic megacolon and/or known small bowel ileus * History of total colectomy or bariatric surgery * Concurrent intensive induction chemotherapy, radiation therapy, or biological treatment for active malignancy * Unable or unwilling to comply with protocol requirements * Expected life expectancy less than 6 months * Previous use of probiotic supplementation (PS) or microbiome-based products within 2 months, large doses of commercial probiotics consumed (greater than or equal to 10\^8 cfu or organisms per day). Includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component (ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply). Enrollment after 2 months without probiotic use can be considered for eligibility * Patients with severe anaphylactic or anaphylactoid food allergy * Solid organ transplant recipients less than or equal to 90 days post-transplant or on active treatment for rejection * A condition that would jeopardize the safety or rights of the participant, would make it unlikely for the participant to complete the study, or would confound the results of the study * Exclusionary factors affecting the microbiome: * Previous use of systemic antibiotics (intravenous, intramuscular, or oral) within 3 months (depends on the duration of antibiotic use, i.e., less than 3 months is considered exclusion, however, enrollment after 3 months without antibiotic use can be considered for eligibility) * Immune stimulating and/or suppressing medications * Immunosuppressed as evaluated by complete blood count (CBC) with differential, which includes white blood cell count, total neutrophil count, and total lymphocyte count * Unstable dietary history during the previous month, which is defined as major changes in diet by eliminating or significantly increasing a major food group * Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years * Major bowel resection at any time * Active uncontrolled gastrointestinal disorders or disease including inflammatory bowel disease, ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (moderate-severe); persistent, infectious gastroenteritis, colitis, or gastritis; persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated), or chronic constipation

Study locations

1 study location is listed.

Recruiting site status is explicitly provided for 1 location; 1 is listed as Recruiting.

Countries: United States

  • Wisconsin, United States: 1

Sample of listed locations

  • University of Wisconsin Hospitals and Clinics — Madison, Wisconsin, 53792, United States — Recruiting

Study details

Start date
September 1, 2026
Primary completion date
September 1, 2029
Completion date
September 1, 2029
First posted
February 17, 2026
Collaborators
International Flavors & Fragrances Inc., National Institute on Aging (NIA)

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07413744
Registry last updated
September 21, 2026
QualifiedStudies registry data refreshed
September 28, 2026
QualifiedStudies record fetched
September 28, 2026

View NCT07413744 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Alzheimers Disease studies | Clinical trial FAQ